相似文献
1
Novel compounds active against Leishmania major.
Antimicrob Agents Chemother. 2006 Feb;50(2):474-9. doi: 10.1128/AAC.50.2.474-479.2006.
2
Inhibition by Dications of in vitro growth of Leishmania major and Leishmania tropica: causative agents of old world cutaneous leishmaniasis.
J Parasitol. 2008 Jun;94(3):743-9. doi: 10.1645/GE-1387.1.
3
Uptake and antileishmanial activity of meglumine antimoniate-containing liposomes in Leishmania (Leishmania) major-infected macrophages.
Int J Antimicrob Agents. 2011 Oct;38(4):341-7. doi: 10.1016/j.ijantimicag.2011.05.012. Epub 2011 Jul 23.
4
Activity of pentostam (sodium stibogluconate) against cutaneous leishmaniasis in mice treated with neutralizing anti-interferon-gamma antibody.
Am J Trop Med Hyg. 1995 Jul;53(1):55-60.
5
Synthesis and in vitro leishmanicidal activity of 2-(5-nitro-2-furyl) and 2-(5-nitro-2-thienyl)-5-substituted-1,3,4-thiadiazoles.
Bioorg Med Chem Lett. 2005 Apr 15;15(8):1983-5. doi: 10.1016/j.bmcl.2005.02.073.
6
Evaluation of leishmanicidal activity and cytotoxicity of Ricinus communis and Azadirachta indica extracts from western Kenya: in vitro and in vivo assays.
BMC Res Notes. 2015 Nov 5;8:650. doi: 10.1186/s13104-015-1605-y.
7
Leishmania donovani: an in vitro study of antimony-resistant amphotericin B-sensitive isolates.
Exp Parasitol. 2006 Dec;114(4):247-52. doi: 10.1016/j.exppara.2006.03.016. Epub 2006 May 23.
8
Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice.
Antimicrob Agents Chemother. 2001 Jun;45(6):1872-5. doi: 10.1128/AAC.45.6.1872-1875.2001.
9
Leishmanicidal and apoptotic activities of oleuropein on Leishmania major.
Int J Clin Pharmacol Ther. 2014 Oct;52(10):880-8. doi: 10.5414/CP202102.
10
Neolignan Licarin A presents effect against Leishmania (Leishmania) major associated with immunomodulation in vitro.
Exp Parasitol. 2013 Oct;135(2):307-13. doi: 10.1016/j.exppara.2013.07.007. Epub 2013 Jul 24.
引用本文的文献
1
Vaccine Designing Technology against Leishmaniasis: Current Challenges and Implication.
Curr Drug Discov Technol. 2025;22(2):e240524230315. doi: 10.2174/0115701638291767240513113400.
2
Genomic Insight of Leishmania Parasite: In-Depth Review of Drug Resistance Mechanisms and Genetic Mutations.
ACS Omega. 2024 Mar 8;9(11):12500-12514. doi: 10.1021/acsomega.3c09400. eCollection 2024 Mar 19.
3
Chitosan-Based Nanomaterials as Valuable Sources of Anti-Leishmanial Agents: A Systematic Review.
Nanomaterials (Basel). 2021 Mar 10;11(3):689. doi: 10.3390/nano11030689.
4
A Systematic Review of Curcumin and its Derivatives as Valuable Sources of Antileishmanial Agents.
Acta Parasitol. 2021 Sep;66(3):797-811. doi: 10.1007/s11686-021-00351-1. Epub 2021 Mar 26.
5
In vitro efficacy of ethanolic extract of Artemisia absinthium (Asteraceae) against Leishmania major L. using cell sensitivity and flow cytometry assays.
J Parasit Dis. 2016 Sep;40(3):735-40. doi: 10.1007/s12639-014-0569-5. Epub 2014 Sep 20.
6
Drug delivery by tattooing to treat cutaneous leishmaniasis.
Sci Rep. 2014 Feb 24;4:4156. doi: 10.1038/srep04156.
7
Comparison of a high-throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assay.
Antimicrob Agents Chemother. 2013 Jul;57(7):2913-22. doi: 10.1128/AAC.02398-12. Epub 2013 Apr 9.
8
9
An image-based high-content screening assay for compounds targeting intracellular Leishmania donovani amastigotes in human macrophages.
PLoS Negl Trop Dis. 2012;6(6):e1671. doi: 10.1371/journal.pntd.0001671. Epub 2012 Jun 12.
10
Metabolic network analysis predicts efficacy of FDA-approved drugs targeting the causative agent of a neglected tropical disease.
BMC Syst Biol. 2012 Apr 27;6:27. doi: 10.1186/1752-0509-6-27.
本文引用的文献
1
Cutaneous leishmaniasis in soldiers returning from deployment to Iraq.
J Am Acad Dermatol. 2004 Nov;51(5 Suppl):S197-200. doi: 10.1016/j.jaad.2004.06.018.
2
In vitro activity of Triclisia patens and some bisbenzylisoquinoline alkaloids against Leishmania donovani and Trypanosoma brucei brucei.
Phytother Res. 2002 Aug;16(5):432-6. doi: 10.1002/ptr.929.
3
A randomized, double-blind study of the efficacy of a 10- or 20-day course of sodium stibogluconate for treatment of cutaneous leishmaniasis in United States military personnel.
Clin Infect Dis. 2002 Aug 1;35(3):261-7. doi: 10.1086/341406. Epub 2002 Jul 10.
4
Visceral leishmaniasis in a New York foxhound kennel.
J Vet Intern Med. 2002 Jan-Feb;16(1):34-44. doi: 10.1892/0891-6640(2002)016<0034:vliany>2.3.co;2.
5
Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice.
Antimicrob Agents Chemother. 2001 Jun;45(6):1872-5. doi: 10.1128/AAC.45.6.1872-1875.2001.
6
Activity of the novel immunomodulatory compound tucaresol against experimental visceral leishmaniasis.
Antimicrob Agents Chemother. 2000 Jun;44(6):1494-8. doi: 10.1128/AAC.44.6.1494-1498.2000.
7
Efficacy of second line drugs on antimonyl-resistant amastigotes of Leishmania infantum.
Acta Trop. 2000 Jan 5;74(1):25-31. doi: 10.1016/s0001-706x(99)00048-0.
8
Trial of oral miltefosine for visceral leishmaniasis.
Lancet. 1998 Dec 5;352(9143):1821-3. doi: 10.1016/S0140-6736(98)04367-0.
9
Leishmania and human immunodeficiency virus coinfection: the first 10 years.
Clin Microbiol Rev. 1997 Apr;10(2):298-319. doi: 10.1128/CMR.10.2.298.
10
Visceral infection caused by Leishmania tropica in veterans of Operation Desert Storm.
N Engl J Med. 1993 May 13;328(19):1383-7. doi: 10.1056/NEJM199305133281904.
Zotero 插件